NASDAQ:MBOT - Nasdaq - US59503A2042 - Common Stock - Currency: USD
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements...
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics...
Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization
Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization...
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market...
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced...
HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for...
HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered...
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025...
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical®...
FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of...
EQNX::TICKER_START (NASDAQ:JFBR),(NASDAQ:SERV),(NASDAQ:SYM),(NASDAQ:MBOT),(NYSE:MDT) EQNX::TICKER_END
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 ...
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for...
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024...
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform The objective of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Microbot Medical (NASDAQ:MBOT) just reported results for the second quarter of ...